What is the role of CRP in glioblastoma?
(2021) In Cancer Treatment and Research Communications 26.- Abstract
Background: Glioblastoma is the most common primary malignant brain tumor in adults. Previous studies have suggested that CRP (C-reactive protein) could serve as a biomarker candidate as well as a prognostic factor in glioblastoma patients, and we here further investigate its potential role. Materials and methods: Publicly available datasets were used to compare gene expression between brain samples from glioblastoma patients and non-tumor tissue. The structure of CRP was compared between humans and rats. Glioblastoma cells from humans and rats were stained with anti-CRP. Fischer 344 rats were inoculated with syngeneic glioblastoma cells pre-coated with anti-CRP, and survival was monitored. CRP concentration in rats carrying... (More)
Background: Glioblastoma is the most common primary malignant brain tumor in adults. Previous studies have suggested that CRP (C-reactive protein) could serve as a biomarker candidate as well as a prognostic factor in glioblastoma patients, and we here further investigate its potential role. Materials and methods: Publicly available datasets were used to compare gene expression between brain samples from glioblastoma patients and non-tumor tissue. The structure of CRP was compared between humans and rats. Glioblastoma cells from humans and rats were stained with anti-CRP. Fischer 344 rats were inoculated with syngeneic glioblastoma cells pre-coated with anti-CRP, and survival was monitored. CRP concentration in rats carrying glioblastoma was followed. Results: CRP was upregulated on one locus on gene level in glioblastoma tissue as compared to non-tumor brain tissue, but not in glioma stem cells as compared to neural stem cells. The structure of the CRP protein was a characteristic pentamer in both humans and rats. Both human and rat glioblastoma cells were clearly positive for anti-CRP staining. Pre-coating of glioblastoma cells with anti-CRP antibodies did not affect survival in rats with intracranial tumors. Serum levels of CRP increased during tumor progression but did not reach significantly different levels. Conclusions: Both human and rat glioblastoma cells could be stained with anti-CRP antibodies in vitro. In a syngeneic glioblastoma rat model we could see an increase in serum CRP during tumor progression, but coating glioblastoma cells with anti-CRP antibodies did not provide any survival change for the animals.
(Less)
- author
- Förnvik, Karolina LU ; Maddahi, Aida LU ; Liljedahl, Emma LU ; Osther, Kurt LU ; Salford, Leif G. LU and Redebrandt, Henrietta Nittby LU
- organization
- publishing date
- 2021
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- C-reactive protein, CRP, Glioblastoma, High grade glioma
- in
- Cancer Treatment and Research Communications
- volume
- 26
- article number
- 100293
- publisher
- Elsevier
- external identifiers
-
- pmid:33385735
- scopus:85098621799
- ISSN
- 2468-2942
- DOI
- 10.1016/j.ctarc.2020.100293
- language
- English
- LU publication?
- yes
- id
- 034ab892-d4ef-4ac3-af95-d30591f3d990
- date added to LUP
- 2021-01-14 07:50:07
- date last changed
- 2024-09-19 14:36:02
@article{034ab892-d4ef-4ac3-af95-d30591f3d990, abstract = {{<p>Background: Glioblastoma is the most common primary malignant brain tumor in adults. Previous studies have suggested that CRP (C-reactive protein) could serve as a biomarker candidate as well as a prognostic factor in glioblastoma patients, and we here further investigate its potential role. Materials and methods: Publicly available datasets were used to compare gene expression between brain samples from glioblastoma patients and non-tumor tissue. The structure of CRP was compared between humans and rats. Glioblastoma cells from humans and rats were stained with anti-CRP. Fischer 344 rats were inoculated with syngeneic glioblastoma cells pre-coated with anti-CRP, and survival was monitored. CRP concentration in rats carrying glioblastoma was followed. Results: CRP was upregulated on one locus on gene level in glioblastoma tissue as compared to non-tumor brain tissue, but not in glioma stem cells as compared to neural stem cells. The structure of the CRP protein was a characteristic pentamer in both humans and rats. Both human and rat glioblastoma cells were clearly positive for anti-CRP staining. Pre-coating of glioblastoma cells with anti-CRP antibodies did not affect survival in rats with intracranial tumors. Serum levels of CRP increased during tumor progression but did not reach significantly different levels. Conclusions: Both human and rat glioblastoma cells could be stained with anti-CRP antibodies in vitro. In a syngeneic glioblastoma rat model we could see an increase in serum CRP during tumor progression, but coating glioblastoma cells with anti-CRP antibodies did not provide any survival change for the animals.</p>}}, author = {{Förnvik, Karolina and Maddahi, Aida and Liljedahl, Emma and Osther, Kurt and Salford, Leif G. and Redebrandt, Henrietta Nittby}}, issn = {{2468-2942}}, keywords = {{C-reactive protein; CRP; Glioblastoma; High grade glioma}}, language = {{eng}}, publisher = {{Elsevier}}, series = {{Cancer Treatment and Research Communications}}, title = {{What is the role of CRP in glioblastoma?}}, url = {{http://dx.doi.org/10.1016/j.ctarc.2020.100293}}, doi = {{10.1016/j.ctarc.2020.100293}}, volume = {{26}}, year = {{2021}}, }